Business Context and Reporting Period
Cocrystal Pharma, Inc. filed a Form 8-K Current Report on January 2, 2019, regarding a material definitive agreement entered into on that date. The Company is a Delaware corporation focused on pharmaceutical development.
Key Financial Metrics
This filing does not provide standard financial statements, revenue, profit, cash flow, or debt metrics. The primary financial disclosure relates to a new commercial agreement:
- Upfront Payment: Cocrystal will receive an upfront sum (specific amount not disclosed in this text).
- Contingent Milestones: Potential to earn up to $156 million in development, regulatory, and sales milestones.
- Royalties: Eligible for royalties on future product sales.
- Funding Structure: Merck Sharp & Dohme Corp. will fund research, development, and clinical trials.
Material Changes
The material change reported is the execution of an Exclusive License and Research Collaboration Agreement with Merck Sharp & Dohme Corp. This agreement grants Merck rights to discover and develop proprietary influenza A/B antiviral agents. Merck assumes responsibility for worldwide commercialization of any resulting products.
Outlook, Risks, and Management Commentary
Outlook: The collaboration positions the Company to monetize its influenza A/B antiviral pipeline through Merck's global commercial infrastructure.
Risks and Contingencies: The Agreement includes termination provisions that can be invoked by either party. Future revenue is contingent upon achieving specific development, regulatory, and sales milestones, which are not guaranteed.
Regulatory Note: The press release announcing this deal (Exhibit 99.1) is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the specific amount of the upfront payment, as it is not detailed in this summary text.
- Review the full text of the Agreement (Exhibit 99.1) to understand the specific milestones required to earn the $156 million.
- Confirm the specific termination triggers and conditions for both parties.
- Assess the impact of this deal on the Company's cash runway and future funding requirements.